TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6376164

Group type: EXPERIMENTAL
Intervention: 10 mg curantyl
Number of subjects: 55

Group type: COMPARATOR
Intervention: 40 mg no-spa
Number of subjects: 55
Study: 31109200

Group type: EXPERIMENTAL
Intervention: Methylphenidate (36 or 54 mg/day of extended-release)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (gradual withdrawal over 3 weeks)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Methylphenidate (continuation group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (discontinuation group)
Number of subjects: 94
Study: 28739058

Group type: EXPERIMENTAL
Intervention: Acupressure bead patch (N=57)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham acupressure patch (N=53)
Number of subjects: 110
Study: 25643863

Group type: EXPERIMENTAL
Intervention: 10 µg Engerix-B
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 20 µg Engerix-B
Number of subjects: 319

Group type: COMPARATOR
Intervention: Non-zero anti-HBs levels (Group 2)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Non-zero anti-HBs levels (Group 3)
Number of subjects: 319
Study: 24094079

Group type: EXPERIMENTAL
Intervention: Double-dose statin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ezetimibe-plus-statin
Number of subjects: 109
Study: 21591571

Group type: EXPERIMENTAL
Intervention: ICD intervention in patients with ischaemic heart disease (IHD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ICD intervention in patients with idiopathic dilated cardiomyopathy (IDCM)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: LVEF < 25% vs 25-34%
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NYHA class
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Positive EPS
Number of subjects: 101
Study: 19155060

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Open pyloromyotomy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study: 19482814

Group type: EXPERIMENTAL
Intervention: Telephone exercise counseling (n = 39)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Combined control groups (n = 42)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Frail participants (n = not specified)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Not frail group (n = not specified)
Number of subjects: 81
Study: 15091267

Group type: EXPERIMENTAL
Intervention: Reamed nail
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unreamed nail
Number of subjects: 45
Study: 11473065

Group type: EXPERIMENTAL
Intervention: Diabetes Network (D‐Net) Active Lives PA Intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Internet information‐only condition
Number of subjects: 78
Study: 9786811

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy alone
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Radioiodine plus prednisone (3-month course, initial dosage 0.4 to 0.5 mg/kg/day)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: High-dose oral prednisone (80 to 100 mg/d for 6 months) and orbital radiation therapy (20 Gy per eye over 2 weeks)
Number of subjects: 450
Study: 7840401

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study: 3146774

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg o.d. in the morning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30700565

Group type: EXPERIMENTAL
Intervention: Device feedback (DF) group (n = 223)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Instructor and device feedback (IDF) group (n = 205)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Device feedback (DF) group
Number of subjects: 653

Group type: COMPARATOR
Intervention: Instructor feedback (IF) group
Number of subjects: 653
Study: 27170277

Group type: EXPERIMENTAL
Intervention: Ultra-mini percutaneous nephrolithotomy (UPNL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (SPNL)
Number of subjects: 97
Study: 26738059

Group type: EXPERIMENTAL
Intervention: Smartphone users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper diary users
Number of subjects: 0
Study: 22884532

Group type: EXPERIMENTAL
Intervention: High-protein enteral diet enriched with ginger
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21481414

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 54
Study: 18277840

Group type: EXPERIMENTAL
Intervention: Fiberglass volar slab
Number of subjects: 84

Group type: COMPARATOR
Intervention: Encircling plaster-of-paris cast
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 16794988

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Maternal anxiety at 12 and 36 months
Number of subjects: 69

Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 69
Study: 14738167

Group type: EXPERIMENTAL
Intervention: Tablet form of misoprostol (400 microg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Capsule form of misoprostol (400 microg)
Number of subjects: 27
Study: 10866895

Group type: EXPERIMENTAL
Intervention: mepivacaine 2% with hyaluronidase
Number of subjects: 60

Group type: COMPARATOR
Intervention: lidocaine 2%-bupivacaine 0.5% mixture with hyaluronidase
Number of subjects: 60
Study: 9339095

Group type: EXPERIMENTAL
Intervention: 200 micrograms of intravaginal misoprostol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3 mg of dinoprostone
Number of subjects: 50
Study: 7692109

Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (2 gm.)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160/800 mg.)
Number of subjects: 599

Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis
Number of subjects: 599
Study: 2877569

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 100
Study: 30267399

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP
Number of subjects: 50

Group type: COMPARATOR
Intervention: 177Lu-EDTMP
Number of subjects: 50
Study: 26223004

Group type: EXPERIMENTAL
Intervention: Yoga exercises
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aerobics exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25570941

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23214304

Group type: EXPERIMENTAL
Intervention: Dental Polis DX toothpaste with propolis content (T)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carepolis gel with propolis content (CT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dental Polis DX toothpaste without propolis content (G)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Carepolis gel without propolis content (CG)
Number of subjects: 80
Study: 20015704

Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream (0.075%) applied to the C(5) dermatome
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical placebo cream applied to the C(5) dermatome
Number of subjects: 40
Study: 18550562

Group type: EXPERIMENTAL
Intervention: Spanish-language version of the World Mental Health Survey Composite International Diagnostic Interview
Number of subjects: 332

Group type: COMPARATOR
Intervention: English-language version of the World Mental Health Survey Composite International Diagnostic Interview
Number of subjects: 332
Study: 15938534

Group type: EXPERIMENTAL
Intervention: Fosinopril (10 mg daily, increased to 20 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Metoprolol (25 mg twice a day, increased to 75 mg)
Number of subjects: 96
Study: 12433513

Group type: EXPERIMENTAL
Intervention: Indo-Mediterranean diet rich in whole grains, fruits, vegetables, walnuts, and almonds
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Local diet similar to the step I National Cholesterol Education Program (NCEP) prudent diet
Number of subjects: 1000
Study: 10369282

Group type: EXPERIMENTAL
Intervention: Preoperative/postoperative Impact
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Postoperative Impact
Number of subjects: 136

Group type: COMPARATOR
Intervention: Postoperative standard formula
Number of subjects: 136

Group type: COMPARATOR
Intervention: Preoperative/postoperative standard formula
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Impact
Number of subjects: 136
Study: 7500456

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mitomycin C and BCG (alternating therapy)
Number of subjects: 68
Study: 2310248

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg up to 10 mg) intravenously three to five minutes before aortic cross‐clamping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no verapamil)
Number of subjects: 40
Study: 382148

Group type: EXPERIMENTAL
Intervention: 10 mg, 20 mg, or 50 mg of domperidone orally
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 8 mg domperidone intravenously
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 30641712

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50000 IU) supplement weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28068951

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 175
Study: 25788397

Group type: EXPERIMENTAL
Intervention: Q‐switched ruby laser (694nm)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ablative CO2 fractional laser (10,600nm)
Number of subjects: 11
Study: 23676191

Group type: EXPERIMENTAL
Intervention: VIABAHN endoprosthesis
Number of subjects: 148

Group type: COMPARATOR
Intervention: bare nitinol stent
Number of subjects: 148
Study: 21835835

Group type: EXPERIMENTAL
Intervention: Research nurse weight estimate using Seca 835‐2 digital paediatric scales
Number of subjects: 156

Group type: COMPARATOR
Intervention: Parental weight estimate using usual home scales
Number of subjects: 156
Study: 19149522

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17224540

Group type: EXPERIMENTAL
Intervention: Dyadic learning group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Solo learning group
Number of subjects: 130
Study: 14698689

Group type: EXPERIMENTAL
Intervention: Numerosity comparison with size and ratio manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison performance with controlled surface area
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relation between comparison performance and verbal counting knowledge
Number of subjects: 0
Study: 14500259

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 105

Group type: COMPARATOR
Intervention: High-concentration oxygen therapy
Number of subjects: 105
Study: 9923765

Group type: EXPERIMENTAL
Intervention: Standardized history and neurologic examination, laboratory tests (complete blood cell count, serum albumin level, vitamin B12 level, and T-lymphocyte subsets), and electrophysiologic testing of sural, tibial, and ulnar nerves
Number of subjects: 251
Study: 7897127

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary revascularization in 1991
Number of subjects: 600

Group type: COMPARATOR
Intervention: Percutaneous coronary revascularization in 1986-1987
Number of subjects: 600
Study: 2311881

Group type: EXPERIMENTAL
Intervention: Nasal oxygen (3 liter/min)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 56
Study: 7426272

Group type: EXPERIMENTAL
Intervention: Young smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smokers (young and elderly)
Number of subjects: 0
Study: 30691328

Group type: EXPERIMENTAL
Intervention: Pharmacist-led telehealth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse-led telehealth
Number of subjects: 0
Study: 30420324

Group type: EXPERIMENTAL
Intervention: Low-dose voclosporin (23.7 mg, twice daily)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: High-dose voclosporin (39.5 mg, twice daily)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 29273661

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (6 messages per week targeting blood pressure control, medication adherence, physical activity, smoking cessation, glucose monitoring, and lifestyle recommendations)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 1300
Study: 25421482

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHG) body wash, frequent use reported by 360 participants (56.3%)
Number of subjects: 1706
Study: 24429379

Group type: EXPERIMENTAL
Intervention: Internet access (IA) group
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-Internet access (NIA) group
Number of subjects: 171
Study: 22936018

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard PCI (without thrombus aspiration)
Number of subjects: 60
Study: 19164322

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily) for 6 months
Number of subjects: 80
Study: 17882570

Group type: EXPERIMENTAL
Intervention: Additional cycle of oral steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no further treatment
Number of subjects: 0
Study: 14630595

Group type: EXPERIMENTAL
Intervention: Lingzhi (1.1g single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lingzhi (3.3g acute dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lingzhi (0.72 g/d for 10 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 12588694

Group type: EXPERIMENTAL
Intervention: High-Fruit and Vegetable (FV) diet
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Low-Fat diet
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination Low-Fat/High-FV diet
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 122
Study: 9686497

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with congestive heart failure class II (n=23)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with congestive heart failure class III (n=26)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with congestive heart failure class IV (n=14)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Plasma adrenomedullin levels in normal subjects (n=30)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels after treatment
Number of subjects: 93
Study: 8294707

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 218
Study: 30803197

Group type: EXPERIMENTAL
Intervention: Reflexology (4 sessions)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 57
Study: 28741652

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine without morphine and postoperative rectus sheath bupivacaine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine with morphine and postoperative rectus sheath saline
Number of subjects: 131
Study: 26109470

Group type: EXPERIMENTAL
Intervention: Intensive treatment (HbA1c <7.0%, blood pressure ≤135/85 mmHg, total cholesterol ≤3.5 mmol/L)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 424
Study: 24295838

Group type: EXPERIMENTAL
Intervention: Video tutorial (10-minute duration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard preoperative consultation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Video tutorial
Number of subjects: 40
Study: 23018531

Group type: EXPERIMENTAL
Intervention: Avagacestat 15, 50, 100 or 150 mg once daily for 28 days (young men)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Avagacestat 50 mg and then 100 mg once daily for 14 days (elderly subjects)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Avagacestat >50 mg/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (young men)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (elderly subjects)
Number of subjects: 52
Study: 19380692

Group type: EXPERIMENTAL
Intervention: Automated software algorithm for volumetric measurement of pulmonary nodules
Number of subjects: 101
Study: 16952511

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 15246797

Group type: EXPERIMENTAL
Intervention: TEAM program (E1 and E2)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control groups (C1 and C2)
Number of subjects: 73
Study: 11739201

Group type: EXPERIMENTAL
Intervention: 24-month cyclosporine prophylaxis
Number of subjects: 162

Group type: COMPARATOR
Intervention: 6-month cyclosporine prophylaxis
Number of subjects: 162
Study: 9404251

Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 27
Study: 8480264

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (PCA-M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient controlled intravenous narcotic analgesia (PCA-M) alone
Number of subjects: 0
Study: 3099651

Group type: EXPERIMENTAL
Intervention: OK‐432 i.v. plus Tegafur
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PSK oral application plus Tegafur
Number of subjects: 172

Group type: COMPARATOR
Intervention: Tegafur oral administration only
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: BRM therapy (OK‐432 and PSK)
Number of subjects: 172
Study: 29977281

Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Observational Practice (OP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Practice (NP) Control
Number of subjects: 30
Study: 26982618

Group type: EXPERIMENTAL
Intervention: 500 mg of H. sabdariffa calyx powder
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24118206

Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation (ONS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 22394534

Group type: EXPERIMENTAL
Intervention: Daily TERT of 6‐12 hr
Number of subjects: 22

Group type: COMPARATOR
Intervention: Daily TERT of 12‐16 hr
Number of subjects: 22
Study: 20035000

Group type: EXPERIMENTAL
Intervention: Three-stage procedure (Group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopic cystectomy (Group 1)
Number of subjects: 20
Study: 19294859

Group type: EXPERIMENTAL
Intervention: Component compatibility group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pieces group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Xuesaitong group
Number of subjects: 120
Study: 15986589

Group type: EXPERIMENTAL
Intervention: Schellong test (ST)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tilt-table test (TT)
Number of subjects: 67
Study: 12653814

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 405
Study: 10337657

Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 3 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 6 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 3 months (clinical C)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 6 months (clinical C)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 259
Study: 7475139

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 1683192

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg qhs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Terfenadine, 60 mg bid
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Terfenadine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 15
Study: 6119776

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg day-1 for 8 consecutive weeks
Number of subjects: 42
Study: 31562043

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2 on days 1-28)
Number of subjects: 371

Group type: COMPARATOR
Intervention: No maintenance chemotherapy (control group)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 371
Study: 30278489

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg (D1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg (D2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 90
Study: 26587881

Group type: EXPERIMENTAL
Intervention: Midvastus approach (MV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medial parapatellar approach (MPP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study: 24468269

Group type: EXPERIMENTAL
Intervention: Intravesical BCG-RIVM strain
Number of subjects: 60
Study: 22456382

Group type: EXPERIMENTAL
Intervention: VASER-assisted lipoplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suction-assisted lipoplasty
Number of subjects: 20